Connecting the dots of Nagakute City – ジブリと里山、文化と歴史がある長久手のWebメディア

「ながくてアートフェスティバル まちNAF みんなつながる!2026」 9月8日〜27日開催記録/長久手のアートの源流は、1966年、長久手村の自然豊かな真っ暗な山奥に愛知県立芸術大学の設立【Nagakute Times】

会場の一つ、リニモテラス内の作品展示

「木について」近藤萌花
 「木一つ一つの違う木々で森はできている」
「お風呂をお先にいただきました」須田やよい 
「お風呂の風呂ふたについた水滴が湯船へと落ちていく。自身の内側で広がっていくイメージや気づき」

「ながくてアートフェスティバル」2026(公式サイトへ)

モリコロパーク・地球市民交流センター

「リサイクル布にモリコロ植物染めで絵を描こう!」NAF芸術家

リサイクル布はスポンサーの日東工業の旧作業服で作ったリサイクル布を使用。顔良やクレヨン、ペンはモリコロパークに生えていた植物で自由に染めたもの
他のSDGs企画として「透明な水うちわを作ろう!」「デコうちわを作ろう!」も開催

「誘惑に支配される人」竹本鉄夫 / 「SDGsの布で時空を遊ぶ」寄川桂

「棲(すま)う」小澤章子
「壺には不可思議な何かが住みついてしまうような気がしてなりません」

「Cetops」竹田歩里
「環境が生物に及ぼすかたちの探究と自身の自然体験と日常のインスピレーションから陶を主成分に制作」

「Gratitude Spiral Rope」安達充徳
「作品のねじれはろくろの回転運動を通してその事実への感謝を形態として定着させた」

この記事を書いた人
1960年 長久手生まれ。上郷保育園、長久手小学校、長久手中学校へ。菊里高校、青山学院大学英米文学科卒。英字新聞部「青山トロージャン」所属。編集プロダクションのMatsuoka & Associatesにて学び、編集工学研究所入所。 1990年、洋書写真集・美術書をリースするArt Bird Books設立、1992年中目黒駅前に店舗を構える。2009年から代官山蔦屋書店にて主に写真集のブックコンシェルジェとして勤務。2020年、Uターンで地元長久手に戻る。 『Canon Photo Circle』誌の写真集コラムを1年間連載後、「長久手タイムズ」を始動。 mail address:nagakutetimes@gmail.com
コメント (101)
  1. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  2. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  3. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  4. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  5. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  6. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  7. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  8. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  9. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  10. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  11. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  12. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  13. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  14. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  15. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  16. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  17. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  18. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  19. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  20. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  21. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  22. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  23. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  24. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  25. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  26. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  27. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  28. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  29. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  30. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  31. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  32. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  33. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  34. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  35. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  36. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  37. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  38. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  39. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  40. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  41. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  42. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  43. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  44. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  45. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  46. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  47. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  48. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  49. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  50. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  51. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  52. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  53. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  54. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  55. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  56. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  57. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  58. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  59. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  60. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  61. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  62. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  63. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  64. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  65. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  66. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  67. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  68. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  69. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  70. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  71. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  72. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  73. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  74. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  75. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  76. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  77. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  78. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  79. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  80. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  81. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  82. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  83. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  84. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  85. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  86. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  87. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  88. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  89. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  90. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  91. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  92. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  93. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  94. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  95. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  96. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  97. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  98. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  99. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  100. SANDRO official より:

    Thanks for this! Any recommended reads about wardrobe essentials?

  101. I got what you intend, thankyou for posting.Woh I am happy to find this website through google. “It is a very hard undertaking to seek to please everybody.” by Publilius Syrus.

コメントを残す

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です